January 8, 2024 02:43 PM EST
Deals
Pharma

Ver­tex backs out of agree­ment with CRISPR Ther­a­peu­tics for stem cell ther­a­py can­di­date in di­a­betes

Katherine Lewin

News Reporter

Ver­tex Phar­ma­ceu­ti­cals’ sub­sidiary Vi­a­Cyte is back­ing out of one of its col­lab­o­ra­tions with CRISPR Ther­a­peu­tics on gene-edit­ed stem cell ther­a­pies for di­a­betes.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times